Effect of OKY-046 and ONO-3708 on liver injury in mice.

The effects of OKY-046, a selective thromboxane A2 (TXA2) synthetase inhibitor, and ONO-3708, a novel TXA2 receptor antagonist, on liver disease were investigated in mice. The liver injury was induced by either an injection of antibasic liver protein (BLP) antibody into DBA/2 mice that had been previously immunized with rabbit IgG or by an injection of bacterial lipopolysaccharide (LPS) into Corynebacterium parvum (C. parvum) pretreated DDY mice. 1) In both injury models, clear elevation of glutamate transaminase (GOT and GPT) activity due to extensive liver parenchymal cell damage was observed; this was confirmed by significant histopathological changes in the liver. 2) Typical histopathological changes in the liver were submassive hepatocellular necrosis in the anti-BLP antibody-induced injury model and focal necrosis in the LPS-induced model. Inflammation and increased cell infiltration in portal connective tissue were observed in both cases. 3) Administration of OKY-046 (50 mg/kg) and ONO-3708 (0.5, 1.0 and 2.0 mg/kg) suppressed the elevation of serum GOT and GPT levels and histopathological changes in both experimental liver injury models. 4) Indomethacin inhibited the development of liver disease caused by anti-BLP antibody but not by bacterial LPS. Prostaglandin I2 inhibited the elevation of serum GOT and GPT levels and histopathological changes of the liver in the mice treated with anti-BLP antibody and showed the tendency to inhibit the development of liver injury caused by bacterial LPS.

[1]  M. Kasahara,et al.  Liver injury model in mice for immunopharmacological study. , 1989, Japanese journal of pharmacology.

[2]  N. Toda,et al.  Endothelium-dependent and independent responses to prostaglandin H2 and arachidonic acid in isolated dog cerebral arteries. , 1988, The Journal of pharmacology and experimental therapeutics.

[3]  T. Itoh,et al.  Mechanisms of vasoconstriction induced by 9,11-epithio-11,12-methano-thromboxane A2 in the rabbit coronary artery. , 1987, Circulation research.

[4]  N. Omawari,et al.  Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046). , 1986, Japanese journal of pharmacology.

[5]  S. Shak,et al.  Production of chemotactic activity for polymorphonuclear leukocytes by cultured rat hepatocytes exposed to ethanol. , 1984, The Journal of clinical investigation.

[6]  K. Decker,et al.  Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells. , 1984, European journal of biochemistry.

[7]  T. E. Little,et al.  Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: Evidence for increased vasoconstrictor and decreased vasodilator factors , 1983 .

[8]  G. Hamilton,et al.  The Relationship Between Prostacyclin Activity and Pressure in the Portal Vein , 2007, Hepatology.

[9]  N. Mafune.  [Purification, characterization and clinical aspects of a liver specific antigen]. , 1982, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[10]  A. M. Lefer,et al.  Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. , 1980, The American journal of physiology.

[11]  P. Walinsky,et al.  Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. , 1979, Prostaglandins and medicine.

[12]  A. Szczeklik,et al.  Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease. , 1978, Acta biologica et medica Germanica.

[13]  M. Hamberg,et al.  Thromboxane A2 and prostaglandin H2: potent stimulators of the swine coronary artery. , 1976, Prostaglandins.

[14]  M. Hamberg,et al.  Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.